Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LXRX

Lexicon Pharmaceuticals Inc

May 29 • 04:00PM ET

2.18

-0.03 -1.36 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: KYMR NUVL RYTM INCY KRYS VKTX BMRN AXSM MDGL NBIX

| Held by: VTI VXF SCHA PRFZ VHT SCHB QQQS BTEC TXS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.07	Insider Own	52.83%	Shs Outstand	423.77M	Perf Week	-2.24%
Market Cap	968.35M	Forward P/E	-	EPS next Y	-0.21	Insider Trans	0.89%	Shs Float	209.55M	Perf Month	40.65%
Enterprise Value	855.40M	PEG	-	EPS next Q	-0.05	Inst Own	29.27%	Short Float	12.47%	Perf Quarter	48.30%
Income	-26.09M	P/S	13.91	EPS this Y	-13.33%	Inst Trans	9.77%	Short Ratio	9.83	Perf Half Y	54.61%
Sales	69.64M	P/B	4.55	EPS next Y	-30.01%	ROA	-9.21%	Short Interest	26.14M	Perf YTD	89.57%
Book/sh	0.48	P/C	5.67	EPS next 5Y	12.50%	ROE	-16.01%	52W High	2.53 -13.83%	Perf Year	230.40%
Cash/sh	0.38	P/FCF	-	EPS past 3/5Y	39.13% 23.47%	ROIC	-10.08%	52W Low	0.62 254.47%	Perf 3Y	-31.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	610.25% 15.72%	Gross Margin	98.70%	Volatility	6.40% 8.10%	Perf 5Y	-50.34%
Dividend TTM	-	EV/Sales	12.28	EPS Y/Y TTM	86.10%	Oper. Margin	-34.79%	ATR (14)	0.14	Perf 10Y	-84.06%
Dividend Ex-Date	-	Quick Ratio	18.77	Sales Y/Y TTM	123.12%	Profit Margin	-37.46%	RSI (14)	58.09	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	18.79	EPS Q/Q	96.28%	SMA20	5.39%	Beta	1.07	Target Price	3.72
Payout	-	Debt/Eq	0.28	Sales Q/Q	1572.11%	SMA50	18.61%	Rel Volume	0.60	Prev Close	2.21
Employees	81	LT Debt/Eq	0.28	Earnings	May 07 BMO	SMA200	48.41%	Avg Volume	2.66M	Price	2.18
IPO	Apr 07, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 115.55%	Trades		Volume	1,602,649	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

May-28-26 08:30AM	Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 08:30AM	Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-07-26 07:46AM	Lexicon: Q1 Earnings Snapshot (Associated Press)
07:30AM	Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire)
May-04-26 04:05PM	Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital (GlobeNewswire)
08:00AM	Loading…
Apr-30-26 08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-17-26 08:00AM	Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire)
Mar-24-26 08:00AM	Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-23-26 07:30AM	Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 (GlobeNewswire) +5.13%
Mar-11-26 08:00AM	Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes (GlobeNewswire)
Mar-10-26 11:26AM	XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study (Zacks)
Mar-05-26 10:10PM	Lexicon Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:35PM	Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
07:21AM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
06:59AM	Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates (GlobeNewswire)
08:15AM	Loading…
Mar-04-26 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-03-26 04:01PM	Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-26 08:30AM	Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Feb-06-26 05:17PM	Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-30-26 02:58PM	Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones (Insider Monkey) -19.44%
02:50AM	Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-29-26 04:31PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:05AM	Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Jan-23-26 08:30AM	Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary (GlobeNewswire)
Jan-21-26 08:30AM	Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +19.08%
Jan-12-26 07:30AM	Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:30AM	Lexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain" (GlobeNewswire)
Jan-07-26 08:30AM	Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 08:30AM	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 (GlobeNewswire)
Dec-05-25 08:30AM	Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum (GlobeNewswire)
08:30AM	Loading…
Nov-25-25 08:30AM	Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences (GlobeNewswire)
Nov-24-25 09:47AM	Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development (Insider Monkey) +5.97%
Nov-11-25 08:30AM	Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference (GlobeNewswire) +9.86%
Nov-08-25 02:30PM	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 (GlobeNewswire)
Nov-06-25 08:50AM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:47AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates (GlobeNewswire)
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:30AM	Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans (GlobeNewswire)
Oct-30-25 08:30AM	Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit (GlobeNewswire)
Oct-08-25 07:59AM	Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain (GlobeNewswire) -5.92%
Sep-22-25 04:00PM	Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-17-25 07:00AM	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings (GlobeNewswire)
Sep-11-25 08:30AM	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings (GlobeNewswire)
Sep-08-25 08:30AM	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-04-25 08:30AM	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 (GlobeNewswire)
Sep-03-25 08:30AM	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 (GlobeNewswire)
Sep-02-25 08:30AM	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress (GlobeNewswire)
Aug-27-25 08:30AM	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 12:00PM	Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-25 08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks) +9.52%
07:47AM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-25 06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks) -6.25%
Jul-31-25 08:00AM	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-23-25 08:00AM	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) (Insider Monkey)
Jul-18-25 08:00AM	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) (GlobeNewswire) -8.89%
Jun-23-25 08:00AM	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-18-25 08:30AM	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

PhDMichael Exton

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Artal Participations S.a r.l.	Director	Apr 30 '26	Option Exercise	0.00	20,421,735	0	175,156,062	May 08 09:45 PM
DEBBANE RAYMOND	Director	Feb 25 '26	Buy	1.49	2,000	2,980	1,906,186	Feb 27 08:33 AM
DEBBANE RAYMOND	Director	Feb 23 '26	Buy	1.47	100,000	147,000	1,904,186	Feb 25 07:00 AM
DEBBANE RAYMOND	Director	Feb 20 '26	Buy	1.48	100,000	147,790	1,804,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 19 '26	Buy	1.44	50,000	71,965	1,704,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 18 '26	Buy	1.32	133,688	176,468	1,654,186	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 17 '26	Buy	1.31	76,857	100,544	1,520,498	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 13 '26	Buy	1.31	57,952	75,877	1,443,641	Feb 18 04:30 PM
Invus Global Management, LLC	Director	Feb 02 '26	Buy	1.30	1,538,462	2,000,001	1,538,462	Feb 04 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your Finviz experience